Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240843 | 0.87 | SMYD3 (0.39) | SMYD3MAPTHTTSMN1; SMN2CHRNB2 | |
| SCHEMBL2728918 | 0.87 | CYP2A6 (0.47) | CYP2A6CYP11B2CYP11B1ARDYRK1A | |
| SCHEMBL5110141 | 0.82 | CYP2A6 (0.42) | CYP2A6CYP11B2CYP11B1ARS1PR1 | |
| Acetic Acid SCHEMBL11638431 | 0.79 | SMN1; SMN2 (0.43) | CYP11B2SMYD3MAPTHTTSMN1; SMN2 | |
| Acetic Acid SCHEMBL6983638 | 0.79 | CYP2A6 (0.43) | CYP2A6CYP11B2CYP11B1ARDYRK1A | |
| SCHEMBL29967583 | 0.77 | HSD17B10 (0.38) | CYP2A6SMN1; SMN2ACHETRPA1 | |
| SCHEMBL4542065 | 0.77 | TDP1 (0.50) | CYP2A6ACHEALDH1A1 | |
| SCHEMBL608438 | 0.76 | ACHE (0.48) | CYP2A6MAPTACHETRPA1ALDH1A1 | |
| SCHEMBL8231933 | 0.76 | ACHE (0.48) | CYP2A6MAPTACHETRPA1ALDH1A1 | |
| SCHEMBL1630903 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX INC (US) | 2022-12-22 | — | — | US | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| CN-101198583-A | Compounds which inhibit beta-secretase activity and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2008-06-11 | — | — | CN | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| EP-1871739-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP2A6 68/4885CYP11B2 117/4885CYP11B1 204/4885 |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | CYP2A6 69/4885CYP11B2 50/4885CYP11B1 80/4885 |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP2A6 3691/4885CYP11B2 1815/4885CYP11B1 1235/4885 |
| US-20220402929-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | CYP2A6 2070/4885CYP11B2 142/4885CYP11B1 118/4885 |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | CYP2A6 4413/4885CYP11B2 4051/4885CYP11B1 3806/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | CYP2A6 68/4885CYP11B2 117/4885CYP11B1 204/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | CYP2A6 4363/4885CYP11B2 3500/4885CYP11B1 3116/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | CYP2A6 3035/4885CYP11B2 1121/4885CYP11B1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.